NBTXR3 First in Class Radioenhancer
Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.
Only one administration
Fits into existing standard of care:
One product addressing areas of high unmet medical needs.
See moreRecent Press Releases
Nanobiotix announces positive first results from phase I expansion in locally advanced head and neck cancer at ASCO 2020
Publication of the 2019 Universal Registration Document
Nanobiotix announces first phase I trial with NBTXR3 in pancreatic cancer is safe to proceed per US FDA
ALL NANOBIOTIX PRESS RELEASE
Events
Meet Nanobiotix International events and conferences
JOIN US
“Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”
Anne-Juliette Hermant
Chief People Officer